 |
|
Long-term Follow-up of Patients With Early-Stage Cutaneous T-Cell Lymphoma Who Achieved Complete Remission With Psoralen Plus UV-A Monotherapy
Christiane Querfeld, MD;
Steven T. Rosen, MD;
Timothy M. Kuzel, MD;
Katharine A. Kirby, MS;
Henry H. Roenigk, Jr, MD;
Bettina M. Prinz, MD;
Joan Guitart, MD
Arch Dermatol. 2005;141:305-311.
Objectives To evaluate long-term outcomes, impact of maintenance therapy and potential curability of patients with mycosis fungoides (MF) treated with psoralen plus UV-A (PUVA) monotherapy.
Design Single-center retrospective cohort analysis.
Setting Academic referral center for cutaneous lymphoma.
Patients A total of 66 of 104 patients with clinical stages IA to IIA MF who achieved complete remission (CR) after PUVA monotherapy between 1979 and 1995.
Main Outcome Measures Kaplan-Meier actuarial survival and disease-free survival curves were compared between stage IA and IB/IIA cases. Patients were stratified into relapse and nonrelapse groups based on whether their MF relapsed during study follow-up. Baseline characteristics and treatment were compared between these groups.
Results Median follow-up time was 94 months (range, 5-242 months). Thirty-three patients maintained CR for 84 months (range, 5-238 months), and 33 patients experienced relapse with a median disease-free interval of 39 months (range, 2-127 months). There was no significant difference in baseline characteristics between patients in the nonrelapse and relapse groups. Those in the nonrelapse group received a higher cumulative dosage to CR (P = .03) and required longer treatment periods to achieve CR (P = .03). Disease-free survival rates at 5 and 10 years for all patients with stage IA were 56% and 30%, respectively, and for stage IB/IIA, 74% and 50%. Actuarial survival rates at 5, 10, and 15 years were 94%, 82%, and 82%, respectively, in patients with stage IA, and 80%, 69%, and 58% in patients with stage IB/IIA. The overall survival rate for the nonrelapse and relapse groups did not show any statistical difference. One third of the patients developed signs of chronic photodamage and secondary cutaneous malignancies.
Conclusions Psoralen UV-A is an effective treatment for MF, inducing long-term remissions and perhaps in some cases disease "cure." Thirty percent to 50% of patients remain disease free for 10 years, but late relapses occur. Long-term survival is not affected by relapse status, and the risk of photodamage needs to be measured against the possible benefit of greater disease elimination.
Author Affiliations: Departments of Dermatology (Drs Querfeld, Roenigk, Prinz, and Guitart), Medicine, Division of Hematology/Oncology, Robert H. Lurie Comprehensive Cancer Center (Drs Rosen and Kuzel), and Preventive Medicine (Ms Kirby), Feinberg School of Medicine, Northwestern University, Chicago, Ill.
RELATED ARTICLES
Health-Related Quality-of-Life Assessment in Patients With Cutaneous T-Cell Lymphoma
Marie-France Demierre, Amy Tien, and Donald Miller
Arch Dermatol. 2005;141(3):325-330.
ABSTRACT
| FULL TEXT
Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma and Neutrophilic Dermatosis
Nathalie Franck, Agnes Carlotti, Isabelle Gorin, Marc Buffet, Christine Mateus, Nicolas Dupin, and for the French Study Group on Cutaneous Lymphomas
Arch Dermatol. 2005;141(3):353-356.
ABSTRACT
| FULL TEXT
Monoclonal T-Cell Dyscrasia of Undetermined Significance Associated With Recalcitrant Erythroderma
Robert Gniadecki and Ansgar Lukowsky
Arch Dermatol. 2005;141(3):361-367.
ABSTRACT
| FULL TEXT
Dyscrasias With "Undetermined Significance"
Günter Burg, Reinhard Dummer, and Werner Kempf
Arch Dermatol. 2005;141(3):382-384.
EXTRACT
| FULL TEXT
Drug-Induced Eosinophilia and Systemic Symptoms: Hypersensitivity or Peripheral T-Cell Lymphoma?
Nicolas Schleinitz, Véronique Veit, Diane Coso, Thérèse Aurran, Phillippe Berbis, and Jean-Robert Harle
Arch Dermatol. 2005;141(3):395-396.
EXTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Primary Cutaneous T-Cell Lymphomas
Rosen and Querfeld
ASH Education Book 2006;2006:323-330.
ABSTRACT
| FULL TEXT
Does PUVA Cure Mycosis Fungoides?
Journal Watch Dermatology 2005;2005:4-4.
FULL TEXT
|
